Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.

The P53 tumor suppressor pathway plays an important role in cancer development. The auto-regulatory feedback mechanism of the P53 and MDM2 expression is critical in keeping proper tumor suppressor function of this pathway. This study examined the effect of P53 Arg72Pro variants on transactivation of polymorphic MDM2 promoter (T309G) and their associations with risk of developing gastric cardia adenocarcinoma (GCA) in a Chinese population. Luciferase assays consistently showed a significantly higher activity of the MDM2 309G promoter compared with the MDM2 309T promoter. In cells co-transfected with variant P53 cDNAs, P53-72Pro displayed a significantly higher ability to activate the MDM2 promoter than P53-72Arg. Genotype analyses in 500 GCA patients and 1000 controls showed that significantly increased risk for developing GCA was associated with the MDM2 309G and the P53 72Pro allele compared with the MDM2 309T and the P53 72Arg allele in an allele dose-dependent manner. A joint effect between the MDM2 and P53 polymorphisms in intensifying GCA risk was detected, with the odds ratio (OR) for the presence of both MDM2 390GG and P53 72Pro/Pro genotypes being 5.05 [95% confidence interval (CI), 2.50-10.20]. These results suggest that the P53 72Pro and MDM2 309G polymorphisms contribute to the risk of developing GCA.

[1]  A. Levine,et al.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.

[2]  M. Zvelebil,et al.  iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.

[3]  L. Donehower,et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[5]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[6]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[7]  Hongbing Shen,et al.  P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. , 2004, Oncology reports.

[8]  M. Blaser,et al.  Population attributable risks of esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.

[9]  M. Gammon,et al.  Nutrient intake and risk of subtypes of esophageal and gastric cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[11]  L. Donehower,et al.  Overexpression of Mdm 2 in mice reveals a p 53-independent role for Mdm 2 in tumorigenesis , 1998 .

[12]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[13]  A. Levine,et al.  Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.

[14]  K. Sabapathy,et al.  Trp53-dependent DNA-repair is affected by the codon 72 polymorphism , 2006, Oncogene.

[15]  S. Wacholder,et al.  A case‐control study of cancer of the esophagus and gastric cardia in linxian , 1989, International journal of cancer.

[16]  W. Mellin,et al.  Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[17]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[18]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[19]  W. Tan,et al.  The Role of P 53 and MDM 2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma , 2005 .

[20]  W. Chow,et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. , 2001, Gastroenterology.

[21]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[22]  B. Wasylyk,et al.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.

[23]  A. Levine,et al.  A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.

[24]  D. Alderson,et al.  Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  F. He,et al.  MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007, Clinical Cancer Research.

[26]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[27]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[28]  H. Saya,et al.  Codon 72 polymorphism of the TP53 gene. , 1990, Nucleic acids research.

[29]  W. Tan,et al.  Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. , 2006, Gastroenterology.

[30]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[31]  M. Oren,et al.  mdm 2 expression is induced by wild type p 53 activity , 2004 .

[32]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[33]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[34]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[35]  E. Brambilla,et al.  Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.

[36]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[37]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[38]  C. Abnet,et al.  Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China , 2005, International journal of cancer.

[39]  Haoyang,et al.  MDM 2 Promoter SNP 309 Is Associated with Risk of Occurrence and Advanced Lymph NodeMetastasis of Nasopharyngeal Carcinoma in Chinese Population , 2007 .

[40]  I. Day,et al.  An efficient procedure for genotyping single nucleotide polymorphisms. , 2001, Nucleic acids research.

[41]  J. Landers,et al.  Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. , 1997, Cancer research.

[42]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[43]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[44]  D. DeMarini.  Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. , 2004, Mutation research.

[45]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[46]  M. Oren,et al.  Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2. , 1996, The EMBO journal.

[47]  Miguel Srougi,et al.  Abnormal Expression of MDM2 in Prostate Carcinoma , 2001, Modern Pathology.